The aforementioned results suggested the miR-148a-3p/SIRT7 axis drives glioma progression and modulates TMZ sensitivity, and targeting this axis may represent a promising therapeutic approach to overcome TMZ resistance in glioma. The gene discussed is SIRT7; the disease is glioma.